secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000320017-24-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics Q2 2024 net loss $5.0M; ASCEND Phase 2b top-line data expected Q4 2024
--------------------------------------------------------------------------------

- Net loss $5.0M in Q2 2024 vs $4.0M in Q2 2023; operating expenses down 19.7% to $5.5M.
- Cash & equivalents $38.3M; funding into early 2026 covering all active trials to data milestones.
- Phase 2b ASCEND trial (certepetide + chemo in mPDAC) top-line results from 95-patient Cohort A on track for Q4 2024.
- BOLSTER Phase 2a in 1L cholangiocarcinoma fully enrolled ahead of plan; topline data mid-2025; 2L cohort added.
- Certepetide received U.S. FDA Orphan Drug and Rare Pediatric Disease designations for osteosarcoma in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000049/0000320017-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000049/clbs-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000320017-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer